ECSP23034914A - Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea - Google Patents

Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea

Info

Publication number
ECSP23034914A
ECSP23034914A ECSENADI202334914A ECDI202334914A ECSP23034914A EC SP23034914 A ECSP23034914 A EC SP23034914A EC SENADI202334914 A ECSENADI202334914 A EC SENADI202334914A EC DI202334914 A ECDI202334914 A EC DI202334914A EC SP23034914 A ECSP23034914 A EC SP23034914A
Authority
EC
Ecuador
Prior art keywords
compositions
treatment
methods
eye disease
thyroid eye
Prior art date
Application number
ECSENADI202334914A
Other languages
English (en)
Inventor
Peter Harwin
Yang Zhao
Angela She
Vahe Bedian
Jonathan Violin
Tomas Kiselak
Original Assignee
Viridian Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=81208791&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP23034914(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Viridian Therapeutics Inc filed Critical Viridian Therapeutics Inc
Publication of ECSP23034914A publication Critical patent/ECSP23034914A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En el presente documento se proporcionan anticuerpos y composiciones contra IGF-1R y los usos de los mismos.
ECSENADI202334914A 2020-10-14 2023-05-11 Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea ECSP23034914A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063091839P 2020-10-14 2020-10-14
US202163201978P 2021-05-21 2021-05-21
US202163260130P 2021-08-10 2021-08-10
US202163261742P 2021-09-28 2021-09-28

Publications (1)

Publication Number Publication Date
ECSP23034914A true ECSP23034914A (es) 2023-06-30

Family

ID=81208791

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202334914A ECSP23034914A (es) 2020-10-14 2023-05-11 Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea

Country Status (18)

Country Link
US (9) US20220267450A1 (es)
EP (1) EP4228616A4 (es)
JP (2) JP2023545520A (es)
KR (1) KR20230124550A (es)
CN (3) CN119792512A (es)
AU (1) AU2021360889A1 (es)
CA (2) CA3195590A1 (es)
CL (1) CL2023001052A1 (es)
CO (1) CO2023005996A2 (es)
CR (1) CR20230204A (es)
DO (1) DOP2023000073A (es)
EC (1) ECSP23034914A (es)
IL (1) IL302068A (es)
JO (1) JOP20230075A1 (es)
MX (1) MX2023004280A (es)
PE (1) PE20231202A1 (es)
TW (2) TW202228775A (es)
WO (2) WO2022081804A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022081804A1 (en) * 2020-10-14 2022-04-21 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2023019171A1 (en) * 2021-08-10 2023-02-16 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
CN119776357A (zh) * 2022-12-06 2025-04-08 中南大学湘雅三医院 一种靶向cd34阳性眼眶成纤维细胞的核酸适配体及其应用
US20250099583A1 (en) 2023-09-06 2025-03-27 Viridian Therapeutics, Inc. Pharmaceutical compositions of anti-igf-1r antibodies
WO2025136985A1 (en) * 2023-12-17 2025-06-26 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
WO2025151492A1 (en) * 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2025151496A1 (en) * 2024-01-09 2025-07-17 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
WO2026044000A1 (en) * 2024-08-20 2026-02-26 Ethyreal Bio, Inc. Multispecific antibodies and methods of use thereof

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4949778A (en) 1987-12-16 1990-08-21 Kawasaki Steel Corporation Immersion nozzle for continuous casting
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
EP1493825A3 (en) 1990-06-11 2005-02-09 Gilead Sciences, Inc. Method for producing nucleic acid ligands
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
PT1498427E (pt) 1992-08-21 2010-03-22 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
DE69427974T2 (de) 1993-04-29 2001-12-06 Unilever N.V., Rotterdam Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
EP0773952B1 (en) 1994-07-20 2003-11-12 The General Hospital Corporation Interaction trap systems for detecting protein interactions
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
AU771534B2 (en) 1999-05-05 2004-03-25 Phylogica Limited Isolating biological modulators from biodiverse gene fragment libraries
JP2003500080A (ja) 1999-05-26 2003-01-07 リセンチア エルテーデー 設計された結合能を有するｓｈ３ドメインを製造するための方法および材料
SE0001877D0 (sv) 2000-05-22 2000-05-22 Klaus Mosbach Molecular imprinting
AU2002218166A1 (en) 2000-09-08 2002-03-22 Universitat Zurich Collections of repeat proteins comprising repeat modules
US7998681B2 (en) 2000-10-06 2011-08-16 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Diagnosis and therapy of antibody-mediated inflammatory auto-immune disorders
US8153121B2 (en) 2000-10-06 2012-04-10 Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
DE10053224A1 (de) 2000-10-26 2002-05-08 Univ Goettingen Georg August Verfahren zur Exposition von Peptiden und Polypeptiden auf der Zelloberfläche von Bakterien
AU2002248184C1 (en) 2000-12-12 2018-01-04 Board Of Regents, The University Of Texas System Molecules with extended half-lives, compositions and uses thereof
EP2284270A3 (en) 2000-12-13 2012-07-25 Anaphore, Inc. Method for the identification and isolation of binding polypeptides from combinatorial libraries of proteins having the scaffold structure of C-type lectin-like domains
NZ527302A (en) 2001-01-05 2006-10-27 Abgenix Inc Antibodies to insulin-like growth factor I receptor
CN1628126A (zh) 2001-08-30 2005-06-15 比奥雷克西斯药物公司 经修饰的运铁蛋白融合蛋白
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
US20030206898A1 (en) * 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
PL210412B1 (pl) 2002-05-24 2012-01-31 Schering Corp Izolowane przeciwciało anty-IGFR lub jego fragment, kompozycja farmaceutyczna, zastosowanie, kwas nukleinowy, zrekombinowany wektor, komórka gospodarza, kompleks, polipeptyd i sposób jego wytwarzania
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US8034904B2 (en) * 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
EP2444809A3 (en) 2002-10-02 2013-07-24 Catalyst Biosciences, Inc. Methods of generating and screening for proteases with altered specificity
ATE500345T1 (de) 2003-01-07 2011-03-15 Dyax Corp Kunitz-domäne-bibliothek
NZ582210A (en) 2003-02-13 2011-04-29 Pfizer Prod Inc Uses of anti-insulin-like growth factor I receptor antibodies
EP1635872A4 (en) 2003-05-30 2008-01-02 Alexion Pharma Inc ANTIBODIES AND FUSION PROTEINS COMPRISING MODIFIED CONSTANT REGIONS
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
AR046639A1 (es) 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
US20060008844A1 (en) 2004-06-17 2006-01-12 Avidia Research Institute c-Met kinase binding proteins
NZ552091A (en) * 2004-07-16 2009-09-25 Pfizer Prod Inc Combination treatment for non-hematologic malignancies using an anti-IGF-1R antibody
DE102004049479A1 (de) 2004-10-11 2006-04-13 Scil Proteins Gmbh Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
MX2007006640A (es) 2004-12-03 2007-06-19 Schering Corp Biomarcadores para la preseleccion de pacientes para la terapia con anti-receptor 1 del factor de crecimiento similar a la insulina.
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
WO2006138315A2 (en) 2005-06-15 2006-12-28 Schering Corporation Anti-igf1r antibody formulations
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
EP1941043B1 (en) * 2005-10-21 2011-04-13 F. Hoffmann-La Roche AG Method for the recombinant expression of a polypeptide
CA2627446A1 (en) 2005-11-21 2007-05-31 Laboratoires Serono S.A. Compositions and methods of producing hybrid antigen binding molecules and uses thereof
US20080014203A1 (en) 2006-04-11 2008-01-17 Silke Hansen Antibodies against insulin-like growth factor I receptor and uses thereof
EP2032989B2 (en) 2006-06-30 2015-10-28 Merck Sharp & Dohme Corp. Igfbp2 biomarker
US8603465B1 (en) 2006-08-07 2013-12-10 Merck Sharp & Dohme, Corp. Methods for treatment of polyposis
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
CN102123712B (zh) * 2006-12-13 2014-03-19 默沙东公司 使用igf1r抑制剂治疗癌症的方法
US20100143340A1 (en) 2006-12-13 2010-06-10 Schering Corporation Methods and compositions for treating cancer
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
WO2008079849A2 (en) * 2006-12-22 2008-07-03 Genentech, Inc. Antibodies to insulin-like growth factor receptor
EP3409687A1 (en) 2007-06-01 2018-12-05 University of Maryland, Baltimore Immunoglobulin constant region fc receptor binding agents
WO2009005673A1 (en) 2007-06-28 2009-01-08 Schering Corporation Anti-igf1r
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
DK2235059T3 (en) 2007-12-26 2015-03-30 Xencor Inc FC-VERSIONS OF MODIFIED BINDING TO FcRn
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
EP2285350B1 (en) 2008-06-16 2017-11-15 Pfizer Inc Methods for the preparation of targeting agent functionalized diblock copolymers for use in fabrication of therapeutic nanoparticles
WO2010006060A2 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
KR20110060911A (ko) 2008-09-26 2011-06-08 쉐링 코포레이션 고 역가 항체 생산
US8137933B2 (en) 2008-11-12 2012-03-20 Schering Corporation Mammalian expression vector pUHAB
JP5719347B2 (ja) * 2009-04-16 2015-05-20 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 癌治療のための組成物及び方法
AU2010242830C1 (en) 2009-05-01 2014-02-13 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
KR101224468B1 (ko) 2009-05-20 2013-01-23 주식회사 파멥신 신규한 형태의 이중표적항체 및 그 용도
UY32808A (es) 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
SG178602A1 (en) 2009-09-01 2012-04-27 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2516624B1 (en) * 2009-12-23 2020-02-05 Merck Sharp & Dohme Corp. Cell line 3m
WO2011161119A1 (en) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Antibodies against insulin-like growth factor i receptor and uses thereof
UY33492A (es) 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
JP5985481B2 (ja) 2010-09-01 2016-09-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 抗イディオタイプ抗体の迅速な産生
US20120263722A1 (en) 2010-11-04 2012-10-18 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
WO2012088302A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
ES2549638T3 (es) 2011-02-28 2015-10-30 F. Hoffmann-La Roche Ag Proteínas de unión a antígeno
CN103403025B (zh) 2011-02-28 2016-10-12 弗·哈夫曼-拉罗切有限公司 单价抗原结合蛋白
JP2014516964A (ja) * 2011-05-18 2014-07-17 メルク・シャープ・アンド・ドーム・コーポレーション 治療用抗ｉｇｆ１ｒ合剤
AU2012255251B2 (en) 2011-05-18 2017-06-15 University Of Florida Research Foundation, Inc. Macrocyclic therapeutic agents and methods of treatment
RS58765B1 (sr) 2011-05-21 2019-06-28 Macrogenics Inc Cd3-vezujući molekuli sposobni za vezivanje za humani i nehumani cd3
MX2014008102A (es) 2011-12-30 2014-09-25 Abbvie Inc Inmunoglobulinas de dominio variable dual contra receptores.
CN110075283A (zh) 2012-02-15 2019-08-02 洛桑聚合联合学院 红细胞结合性治疗剂
EP2852685A1 (en) * 2012-03-30 2015-04-01 Merck Sharp & Dohme Corp. Igf1 biomarker for igf1r inhibitor therapy
US10519245B2 (en) 2012-06-21 2019-12-31 Sorrento Therapeutics Inc. Antibodies which bind insulin-like growth factor receptor-1 (IGF1R) and methods of use thereof to treat cancer
EP2970433B1 (en) 2013-03-13 2019-09-18 Bioasis Technologies Inc. Fragments of p97 and uses thereof
SG11201508911PA (en) * 2013-04-29 2015-11-27 Hoffmann La Roche Human fcrn-binding modified antibodies and methods of use
US20160068613A1 (en) * 2013-04-29 2016-03-10 Hoffmann-La Roche Inc. Fc-receptor binding modified asymmetric antibodies and methods of use
CN105164158A (zh) 2013-04-29 2015-12-16 豪夫迈·罗氏有限公司 消除对FcRn-结合的抗-IGF-1R抗体及其在血管性眼病治疗中的用途
ES2923641T3 (es) 2013-12-30 2022-09-29 Epimab Biotherapeutics Inc Inmunoglobulina con Fabs en tándem y usos de la misma
US20210138076A2 (en) 2014-01-27 2021-05-13 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
WO2016004389A2 (en) 2014-07-03 2016-01-07 Abbvie Inc. Monovalent binding proteins
WO2016064716A1 (en) 2014-10-20 2016-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination therapy of tshr antagonist and igfr inhibitor
WO2017011773A2 (en) 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
WO2017186928A1 (en) 2016-04-29 2017-11-02 Curevac Ag Rna encoding an antibody
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
CN109803679A (zh) 2016-08-30 2019-05-24 得克萨斯州大学系统董事会 在基因组重新编码生物体中生产硒代生物制剂
EP3516068B1 (en) 2016-09-19 2025-04-23 University of Southern California Non-radioactive cytotoxicity assays
US10722589B2 (en) 2017-04-03 2020-07-28 Covagen Ag FGFR3 binding molecules
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
CN110891614A (zh) * 2017-05-05 2020-03-17 融合制药公司 Igf-1r单克隆抗体及其用途
KR20220051270A (ko) 2017-05-30 2022-04-26 데이진 화-마 가부시키가이샤 항 igf-i 수용체 항체
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
EP3700901A1 (en) 2017-10-24 2020-09-02 Genentech, Inc. (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
US20210284741A1 (en) 2018-01-24 2021-09-16 Hznp Limited Methods for the treatment of thyroid eye disease
US11208490B2 (en) * 2018-03-05 2021-12-28 Horizon Therapeutics Ireland Dac Methods for the treatment of thyroid eye disease
US11208489B2 (en) * 2018-01-24 2021-12-28 Horizon Therapeutics Ireland Dac Methods for the treatment of thyroid eye disease
WO2019183523A1 (en) 2018-03-23 2019-09-26 Genentech, Inc. Hetero-bifunctional degrader compounds and their use as modulators of targeted ubiquination (vhl)
EP3546362B1 (en) * 2018-03-28 2024-01-24 Airbus Operations GmbH Fuselage assembly for an aircraft
CA3103374A1 (en) 2018-06-29 2020-01-02 Krystal Biotech, Inc. Compositions and methods for antibody delivery
JP6958530B2 (ja) * 2018-10-10 2021-11-02 セイコーエプソン株式会社 光学モジュールおよび頭部装着型表示装置
EP3890789A4 (en) * 2018-12-03 2022-12-14 Fusion Pharmaceuticals Inc. COMBINATION RADIOIMMUNOCONJUGATE AND CHECKPOINT INHIBITOR THERAPY
PH12021551458A1 (en) * 2018-12-19 2022-05-02 Humabs Biomed Sa Antibodies that neutralize hepatitis b virus and uses thereof
EP4021500A4 (en) 2019-08-28 2023-09-06 Horizon Therapeutics Ireland Dac METHOD FOR TREATING THYROID EYE DISEASE
CN113402602B (zh) 2020-03-17 2022-09-23 上海祥耀生物科技有限责任公司 一种新型冠状病毒SARS-CoV-2中和性抗体及应用
WO2021243014A1 (en) 2020-05-28 2021-12-02 Horizon Therapeutics Ireland Dac Methods for the treatment of idiopathic orbital inflammation and related conditions
WO2022081804A1 (en) 2020-10-14 2022-04-21 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
TW202246339A (zh) 2021-03-03 2022-12-01 愛爾蘭商赫萊森治療愛爾蘭公司 治療甲狀腺眼疾的方法
EP4123454A1 (en) 2021-07-21 2023-01-25 Abb Schweiz Ag Validating component specifications for industrial automation systems
WO2023019171A1 (en) 2021-08-10 2023-02-16 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
AU2022341030A1 (en) 2021-09-01 2023-11-30 Biosceptre (Aust) Pty Ltd Methods and compositions for stimulating immune activity
JP2025501028A (ja) 2021-12-23 2025-01-16 ヴィリディアン セラピューティクス，インコーポレーテッド 甲状腺眼疾患を治療するための組成物及び方法
AU2023205789A1 (en) 2022-01-07 2024-07-18 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
JP2025503339A (ja) 2022-01-07 2025-02-03 ヴィリディアン セラピューティクス，インコーポレーテッド 甲状腺眼疾患を治療するための組成物及び方法
IL314154A (en) 2022-01-09 2024-09-01 Kriya Therapeutics Inc Vector constructs for delivery of nucleic acids encoding anti-IGF-1R therapeutic antibodies and methods of using them
WO2025014773A1 (en) 2023-07-07 2025-01-16 Viridian Therapeutics, Inc. Methods of treating chronic thyroid eye disease
US20250099583A1 (en) 2023-09-06 2025-03-27 Viridian Therapeutics, Inc. Pharmaceutical compositions of anti-igf-1r antibodies

Also Published As

Publication number Publication date
EP4228616A1 (en) 2023-08-23
IL302068A (en) 2023-06-01
US12404335B2 (en) 2025-09-02
AU2021360889A1 (en) 2023-06-15
EP4228616A4 (en) 2025-02-12
WO2022081804A1 (en) 2022-04-21
PE20231202A1 (es) 2023-08-17
US20220275096A1 (en) 2022-09-01
CA3195512A1 (en) 2022-04-21
US11548951B1 (en) 2023-01-10
CL2023001052A1 (es) 2023-11-17
US20230279122A1 (en) 2023-09-07
WO2022081799A1 (en) 2022-04-21
TW202228775A (zh) 2022-08-01
TW202229350A (zh) 2022-08-01
KR20230124550A (ko) 2023-08-25
CN119792512A (zh) 2025-04-11
CN116583273B (zh) 2025-01-14
US20220235137A1 (en) 2022-07-28
JOP20230075A1 (ar) 2023-04-13
JP2023545520A (ja) 2023-10-30
JP2025143343A (ja) 2025-10-01
US20250382374A1 (en) 2025-12-18
CA3195590A1 (en) 2022-04-21
US20220267450A1 (en) 2022-08-25
CN119792513A (zh) 2025-04-11
US20250313639A1 (en) 2025-10-09
US20220267451A1 (en) 2022-08-25
MX2023004280A (es) 2023-06-23
CN116583273A (zh) 2023-08-11
US20240043546A1 (en) 2024-02-08
US20250059287A1 (en) 2025-02-20
CR20230204A (es) 2023-10-11
DOP2023000073A (es) 2023-09-29
US20230002495A1 (en) 2023-01-05
CO2023005996A2 (es) 2023-05-29

Similar Documents

Publication Publication Date Title
ECSP23034914A (es) Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea
MX2024008529A (es) Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea.
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
CO2019002239A2 (es) Formulaciones, kits y métodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados
AR105600A1 (es) Anticuerpos contra la angiopoyetina implicada en metabolismo de los triglicéridos (anti-angptl8) y usos de los mismos
CL2019001043A1 (es) Anticuerpos anti-il-33 y usos de los mismos.
CL2017000651A1 (es) Anticuerpos anti-glucagón y sus usos
MX2015011131A (es) Composiciones, formulaciones y metodos para tratar enfermedades oculares.
MX391279B (es) Anticuerpos biespecíficos contra cd3 y cd20.
CO2022002573A2 (es) Anticuerpos contra ilt2 y uso de los mismos
MX2021013657A (es) Conjugados de anticuerpo y farmaco.
MX2018003542A (es) Metodos para tratar presion intraocular con activadores de tie-2.
MX2025003354A (es) Anticuerpos que se unen a 5t4
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
MX2020005555A (es) Construcciones inmunogenicas de peptidos de tau.
MX2016013598A (es) Lente intraocular secundaria con porcion optica coaxial amplificadora.
CO2023002375A2 (es) Anticuerpos contra ilt2 y uso de los mismos
MX2021005751A (es) Anticuerpos contra mucina 16 y métodos de uso de los mismos.
CO2023012639A2 (es) Métodos para el tratamiento de la enfermedad ocular tiroidea
MX2024008530A (es) Composiciones y metodos para el tratamiento de la enfermedad ocular tiroidea.
MX385698B (es) Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares
CL2023001596A1 (es) Composiciones y métodos para el tratamiento de enfermedades oculares
DOP2024000117A (es) Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
CL2019000471A1 (es) Formas sólidas de un compuesto de dihidroxi ciclopentilo disustituido con alfa, omega y métodos para su preparación y uso. (divisional solicitud 201601448)